Crocs, Inc.
CROX
$122.24
-0.62%
Crocs, Inc. designs, develops, markets, and distributes casual lifestyle footwear and accessories for men, women, and children, operating through two reportable segments: the core Crocs Brand and the acquired HEYDUDE Brand, with the Crocs Brand generating the overwhelming majority of revenue. The company is a global leader in the casual, molded-footwear niche, distinguished by its proprietary Croslite material and a brand identity that straddles utilitarian comfort and fashion relevance, giving it pricing power unusual for a footwear maker. The current investor narrative is dominated by the turnaround of the struggling HEYDUDE acquisition, which has been a persistent earnings drag and the central overhang on the stock, set against a resilient core Crocs Brand and a deeply discounted valuation. Recent headlines highlight a wave of analyst upgrades citing brand recovery and an attractive multiple, even as debate continues over whether HEYDUDE can be stabilized or should be divested.…
CROX
Crocs, Inc.
$122.24
Related headlines
Investment Opinion: Should I buy CROX Today?
The synthesized recommendation is Buy, with the core thesis that Crocs' 8.18x forward PE and 0.52 PEG dramatically undervalue a business generating 56.75% gross margins and $670.66 million in trailing free cash flow, while the consensus average target of $138.25 implies 13.1% upside and the high target of $163.00 implies 33%. The recent upgrades from Piper Sandler, Baird, and Seaport Global, set against a single Sell from Goldman Sachs, suggest sentiment is turning but not yet euphoric.
Supporting evidence is strong: the forward PE of 8.18x is roughly 40-50% below the mid-to-high-teens multiple typical of branded footwear peers; the PS ratio of 1.15x is near the low end of the stock's historical 3.1x-14x range; Q1 2026 operating margin of 21.80% and net margin of 14.93% show the core business remains highly profitable; and TTM free cash flow of $670.66 million funds buybacks and debt reduction internally. The forward EPS estimate of $14.83, if achieved, would make the current price look inexpensive on any normalized basis, and the PEG of 0.52 suggests the market is not paying for growth.
Key risks that could invalidate the thesis are HEYDUDE's continued drag (it contributed only 17% of revenue but drove the -$759.21 million Q2 2025 impairment), revenue stagnation (Q1 2026 down 1.69% YoY), and gross margin compression (56.75% in Q1 2026 versus 58.52% in Q3 2025). The rating would upgrade to a stronger Buy if HEYDUDE losses are contained and revenue returns to growth, and would downgrade to Hold or Sell if revenue declines accelerate or gross margin falls below 55%. On balance, the stock appears undervalued relative to its history and peers, but the discount reflects real execution risk that must be monitored.
Sign up to view all
CROX 12-Month Price Forecast
The risk/reward is skewed favorably: an 8.18x forward PE, 0.52 PEG, and 1.15x PS ratio price in substantial pessimism, while the core brand's 56.75% gross margin and $670.66 million in trailing free cash flow demonstrate the business remains highly cash-generative. The recent upgrades from Piper Sandler, Baird, and Seaport Global, plus 13.1% average target upside, suggest sentiment is improving, though the wide $95-$163 target range and Goldman Sachs Sell rating show conviction is fragile. The key swing factor is HEYDUDE: if losses are contained and revenue stabilizes, the multiple should expand toward peer levels; if not, the stock remains a value trap. I would upgrade to high confidence if Q2 2026 shows positive revenue growth and stable gross margin, and downgrade to neutral if revenue declines accelerate or gross margin falls below 55%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Crocs, Inc.'s 12-month outlook, with a consensus price target around $138.25 and implied upside of +13.1% versus the current price.
Average Target
$138.25
0 analysts
Implied Upside
+13.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$95 - $163
Analyst target range
Twelve analysts cover Crocs, and the consensus average target price is $138.25, which implies roughly 13.1% upside from the current price of $122.24. The distribution of ratings is mixed but leans constructive: recent actions include Piper Sandler upgrading to Overweight from Neutral (June 26, 2026), Baird upgrading to Outperform from Neutral (June 8, 2026), and Seaport Global upgrading to Buy from Neutral (April 14, 2026), while Goldman Sachs maintains a Sell and Stifel, UBS, and Barclays remain neutral. The upgrade trend from multiple houses over the past several months signals improving sentiment, though the presence of a Sell rating and several Holds means the consensus is best characterized as moderately bullish rather than uniformly positive. The full target range spans $95.00 to $163.00, a wide spread of $68 (roughly 56% of the current price), which signals meaningful disagreement about the company's trajectory. The high target of $163.00 implies roughly 33% upside and likely assumes successful HEYDUDE stabilization, revenue reacceleration, and multiple expansion toward peer levels as earnings normalize. The low target of $95.00 implies about 22% downside and prices in continued HEYDUDE weakness, margin compression, and skepticism that the forward EPS estimate of $14.83 is achievable. The wide spread, combined with the recent cluster of upgrades, suggests conviction is building but remains fragile, and the stock's high beta of 1.514 means target revisions could drive outsized price moves; investors should watch whether the consensus target migrates toward the high end as HEYDUDE results clarify.
Drowning in data?
Find the real signal!
Bulls vs Bears: CROX Investment Factors
The bull case currently has stronger evidence: an 8.18x forward PE, 0.52 PEG, 56.75% gross margin, $670.66 million TTM free cash flow, and a recent cluster of analyst upgrades with 13.1% average target upside. The bear case is credible but largely backward-looking, resting on the Q2 2025 impairment, flat revenue, and HEYDUDE uncertainty. The single most important tension is whether the forward EPS of $14.83 is achievable — if HEYDUDE losses are contained and revenue stabilizes, the discount looks unwarranted; if not, the stock is a value trap. Near-term momentum has cooled (down 2.78% over one month, relative strength of -1.82 versus SPY), so the market is in a wait-and-see posture ahead of the next HEYDUDE datapoint.
Bullish
- Deep value on forward earnings: CROX trades at just 8.18x forward EPS of $14.83, roughly a 40-50% discount to the mid-to-high-teens forward multiple typical of established branded footwear peers. The PEG ratio of 0.52 (well below 1.0) signals the market is not paying for expected growth, and the 1.15x PS ratio sits near the low end of the stock's multi-year band (historically 3.1x to over 14x).
- Core brand profitability remains elite: The core Crocs Brand generated $767.42 million of the $921.46 million in Q1 2026 revenue, and company-level gross margin was 56.75% with a 21.80% operating margin and $200.84 million of operating income. These margins are unusually high for footwear and demonstrate real pricing power from the proprietary Croslite material.
- Strong free cash flow funds capital returns: Trailing free cash flow was $670.66 million, comfortably covering interest expense (interest coverage of 9.82x) and funding buybacks and debt reduction. The Q1 2026 FCF of -$71.15 million was driven by a seasonal -$258.43 million working-capital swing, mirroring Q1 2025's -$82.61 million, so it is not structural deterioration.
- Analyst upgrades and 13% target upside: The consensus average target of $138.25 implies 13.1% upside from $122.24, with a high target of $163.00 implying 33% upside. Piper Sandler (June 26, 2026), Baird (June 8, 2026), and Seaport Global (April 14, 2026) all upgraded recently, signaling improving sentiment even as Goldman Sachs maintains a Sell.
Bearish
- Revenue is stagnating, not growing: Q1 2026 revenue of $921.46 million declined 1.69% YoY versus $937.33 million in Q1 2025, and the multi-quarter trend shows oscillation between $921 million and $1,149 million rather than growth. The investment case therefore rests entirely on margin recovery and capital returns, not top-line acceleration.
- HEYDUDE is a persistent earnings drag: HEYDUDE contributed only $154.04 million (about 17%) of Q1 2026 revenue but has been the primary source of volatility and impairment charges, including the -$759.21 million other-expense line in Q2 2025. Until HEYDUDE is stabilized or divested, the overhang on the stock is likely to persist.
- Gross margin is compressing: Gross margin fell to 56.75% in Q1 2026 from 58.52% in Q3 2025 and 57.78% in the prior-year Q1, suggesting pricing or cost pressure. If this compression continues, the forward EPS estimate of $14.83 could prove optimistic.
- Leverage and high beta amplify risk: Debt-to-equity of 1.25 and total debt-to-capitalization of 54.73% leave the balance sheet exposed if earnings disappoint, while the beta of 1.514 means the stock is roughly 51% more volatile than the market. The maximum drawdown of -24.25% over the period underscores the potential for sharp swings.
CROX Technical Analysis
Crocs is in a sustained recovery uptrend, with the shares up 52.11% over the trailing year and 61.31% over six months, a dramatic rebound from a 52-week low of $73.21. At the current price of $122.24, the stock sits at roughly 72% of its 52-week range (low $73.21 to high $141.28), positioning it in the upper half of the band but still about 13.5% below the high, which suggests momentum with room to run rather than an overextended blow-off top. The 1-year relative strength versus SPY of +37.10 percentage points confirms genuine market leadership over the longer horizon. Near-term momentum, however, has cooled: the stock is down 2.78% over the past month and 2.25% over three months, diverging sharply from the powerful 1-year and 6-month gains. This deceleration, with relative strength of -1.82 over one month and -4.25 over three months versus SPY, signals a consolidation or digestion phase rather than a trend reversal, especially given the stock's recovery from the September 10 low of $108.83 back to $122.24 in just over a week. The recent bounce off that $108-111 area suggests buyers are defending the pullback, though the failure to reclaim the August highs near $141 keeps the near-term picture neutral-to-cautious. Key resistance sits at the 52-week high of $141.28, and a decisive breakout above that level would confirm a resumption of the primary uptrend and likely draw momentum capital; support is anchored at the 52-week low of $73.21, with intermediate support around the recent $108-111 consolidation zone. A breakdown below $108 would threaten the recovery structure and open the door to a retest of the low-$100s, while the stock's beta of 1.514 means it is roughly 51% more volatile than the broader market, a critical consideration for position sizing and stop placement. The maximum drawdown of -24.25% over the period underscores that this is a high-beta name capable of sharp swings in both directions.
Beta
1.51
1.51x market volatility
Max Drawdown
-24.3%
Largest decline past year
52-Week Range
$73-$141
Price range past year
Annual Return
+52.1%
Cumulative gain past year
| Period | CROX Return | S&P 500 |
|---|---|---|
| 1m | -2.8% | -0.5% |
| 3m | -2.2% | +2.3% |
| 6m | +61.3% | +16.6% |
| 1y | +52.1% | +14.8% |
| ytd | +40.6% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CROX Fundamental Analysis
Revenue has been essentially flat to slightly declining, with the most recent quarter (Q1 2026, ended March 31) posting $921.46 million, a YoY decline of 1.69% versus the prior-year quarter's $937.33 million. The multi-quarter trend shows revenue oscillating in a narrow band: $957.64 million in Q4 2025, $996.30 million in Q3 2025, and a peak of $1,149.37 million in Q2 2025, indicating the top line has stagnated rather than grown. Segment data reveals the core Crocs Brand at $767.42 million versus HEYDUDE at $154.04 million, meaning HEYDUDE contributes only about 17% of revenue but has been the primary source of volatility and impairment charges. The flat growth profile implies the investment case rests on margin recovery and capital returns rather than top-line acceleration, making execution on HEYDUDE and pricing discipline on the core brand the key swing factors. Profitability remains solid at the operating level, with Q1 2026 gross margin of 56.75% and operating margin of 21.80%, generating $200.84 million in operating income and $137.56 million in net income (a 14.93% net margin). However, the trailing-twelve-month picture is distorted by a massive Q2 2025 loss of -$492.28 million, driven by a -$759.21 million other-expense line (likely a HEYDUDE impairment), which dragged TTM EPS to -$0.02 and net margin to -2.01%. Gross margin has compressed modestly from 58.52% in Q3 2025 to 56.75% in Q1 2026, and from 57.78% in the prior-year Q1, suggesting some pricing or cost pressure, though the 21.97% operating margin remains healthy for the footwear industry. The key question is whether the impairment was a one-time clean-up that clears the deck for cleaner earnings, which the forward EPS estimate of $14.83 strongly implies. The balance sheet carries meaningful leverage, with a debt-to-equity ratio of 1.25 and total debt-to-capitalization of 54.73%, though interest coverage of 9.82x on operating income provides an adequate cushion. Liquidity is reasonable with a current ratio of 1.27, and the company generated $670.66 million in trailing free cash flow, a robust figure that funds buybacks and debt reduction internally. Notably, Q1 2026 free cash flow was -$71.15 million due to a -$258.43 million working-capital swing (largely receivables and inventory build), a seasonal pattern also seen in Q1 2025's -$82.61 million, so it should not be read as structural deterioration. ROE on a trailing basis is distorted at -6.28% by the impairment, but the underlying quarterly ROE (e.g., 9.64% in Q1 2026 per historical ratios) shows the business remains capital-efficient, and the company has been actively retiring shares and debt, signaling confidence in internal cash generation.
Quarterly Revenue
$921457000.0B
2026-03
Revenue YoY Growth
-1.7%
YoY Comparison
Gross Margin
56.8%
Latest Quarter
Free Cash Flow
$670662000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CROX Overvalued?
Because trailing net income is negative (TTM EPS of -$0.02, driven by the Q2 2025 impairment), the trailing PE of -57.01x is not meaningful, so the appropriate primary metric is the forward PE, which stands at a remarkably low 8.18x against forward EPS estimates of $14.83. This single-digit forward multiple is the crux of the bull case: the market is pricing Crocs as if earnings will remain depressed, despite consensus expecting a sharp rebound. The gap between the meaningless trailing PE and the 8.18x forward PE implies the market expects a dramatic earnings normalization, and the PEG ratio of 0.52 (well below 1.0) suggests the stock is cheap relative to its expected growth rate. On a price-to-sales basis, the 1.15x PS ratio is low in absolute terms, while the EV/EBITDA of 25.44x appears elevated only because trailing EBITDA is depressed by the impairment; on normalized EBITDA the multiple would be far lower. Compared with the broader apparel and footwear sector, where established branded names typically trade at mid-to-high-teens forward earnings multiples, Crocs' 8.18x forward PE represents a substantial discount of roughly 40-50%, and its 1.15x PS ratio is well below the sector norm. The premium/discount debate hinges on whether the discount is justified by HEYDUDE uncertainty and leverage (D/E of 1.25) or is an unwarranted pessimism that ignores the core brand's 56.75% gross margin and 21.97% operating margin. Given the profitability and cash generation of the core business, the discount looks excessive, though the market is clearly demanding proof that HEYDUDE losses are contained and that revenue can stabilize. Historically, Crocs has traded at a wide range of multiples: its PS ratio has ranged from roughly 3.1x (Q2 2022) to over 14x (Q3 2021), and its PE has swung from the mid-single digits to the mid-teens in profitable quarters. The current PS of 1.15x is near the low end of its multi-year band, and the forward PE of 8.18x is toward the bottom of its historical range, suggesting the stock is priced for pessimism. This positioning means either a value opportunity if earnings normalize as consensus expects, or a value trap if HEYDUDE deterioration and revenue stagnation persist; the historical context tilts the risk/reward favorably but does not eliminate the execution risk.
PE
-57.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 4x~16x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
25.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the HEYDUDE segment and the balance sheet. HEYDUDE generated only $154.04 million of Q1 2026 revenue (about 17% of the total) but has driven the bulk of earnings volatility, including the -$759.21 million other-expense line in Q2 2025 that produced a -$492.28 million net loss and dragged TTM EPS to -$0.02. Revenue is stagnating, with Q1 2026 down 1.69% YoY, so the entire thesis depends on margin recovery rather than growth. Leverage adds risk: debt-to-equity of 1.25 and total debt-to-capitalization of 54.73%, though interest coverage of 9.82x and $670.66 million in TTM free cash flow provide an adequate cushion. Gross margin compression from 58.52% in Q3 2025 to 56.75% in Q1 2026 is a warning sign that pricing or cost pressure could undermine the $14.83 forward EPS estimate.
Market and competitive risks are amplified by the stock's high beta of 1.514, meaning it is roughly 51% more volatile than the broader market and highly sensitive to sector rotation and macro shifts. The forward PE of 8.18x is a discount to peers, but if the market decides the discount is justified by HEYDUDE uncertainty and leverage, multiple compression could continue even as earnings normalize. Competitive disruption in casual footwear is a real threat, and the recent news flow highlights that the HEYDUDE overhang remains the central debate. Near-term relative strength is negative (-1.82 over one month, -4.25 over three months versus SPY), suggesting the stock is in a consolidation phase that could persist if upcoming results disappoint.
The worst-case scenario is a HEYDUDE deterioration combined with revenue stagnation and margin compression, which would validate the bear case and push the stock toward the analyst low target of $95.00 (about 22% downside) or even the 52-week low of $73.21 (about 40% downside from $122.24). A breakdown below the $108-111 consolidation zone would threaten the recovery structure and open the door to a retest of the low-$100s, with the 52-week low as the ultimate floor. Given the maximum drawdown of -24.25% over the period and the high beta, an adverse scenario could realistically cost an investor 22-40% from the current price.
FAQ
The most severe risk is company-specific: HEYDUDE contributed only 17% of Q1 2026 revenue but drove the -$759.21 million other-expense line in Q2 2025 that produced a -$492.28 million net loss, and further deterioration could force another impairment. Second is financial risk: debt-to-equity of 1.25 and total debt-to-capitalization of 54.73% leave the balance sheet exposed if earnings disappoint, though interest coverage of 9.82x provides a cushion. Third is operational risk: revenue declined 1.69% YoY in Q1 2026 and gross margin compressed from 58.52% in Q3 2025 to 56.75% in Q1 2026, so the forward EPS of $14.83 may prove optimistic. Fourth is market risk: the beta of 1.514 means the stock is roughly 51% more volatile than the market, and the maximum drawdown of -24.25% over the period shows how sharply it can fall. Ranked by severity, the HEYDUDE overhang is first, followed by revenue stagnation, leverage, and macro-driven multiple compression.
The 12-month forecast has three scenarios: a bull case with 30% probability targeting $155-$163 (analyst high of $163.00), a base case with 50% probability targeting $130-$145 (consensus average of $138.25), and a bear case with 20% probability targeting $95-$108 (analyst low of $95.00). The base case is most likely, assuming forward EPS of $14.83 is achieved within 10%, gross margin holds above 55%, and HEYDUDE revenue stabilizes around $150-160 million per quarter. The bull case requires HEYDUDE to return to positive operating income and revenue growth to turn positive, driving multiple expansion toward peer levels. The bear case would be triggered by another HEYDUDE impairment, revenue declines exceeding 3% YoY, or gross margin falling below 55%. The wide $95-$163 target range reflects genuine disagreement, and the high beta means actual outcomes could overshoot these ranges.
CROX appears undervalued on forward earnings: the 8.18x forward PE is roughly 40-50% below the mid-to-high-teens multiple typical of established branded footwear peers, and the 0.52 PEG ratio is well below 1.0. The 1.15x PS ratio sits near the low end of the stock's historical range of roughly 3.1x to over 14x, and the forward PE is toward the bottom of its historical band. The trailing PE of -57.01x is not meaningful because TTM EPS of -$0.02 is distorted by the Q2 2025 impairment, so the forward multiple is the relevant gauge. The market is effectively pricing in that the $14.83 forward EPS estimate is at risk, which implies skepticism about HEYDUDE stabilization and revenue growth. If earnings normalize as consensus expects, the discount looks excessive; if not, the valuation is fair or even generous.
From a risk/reward perspective, CROX offers 13.1% upside to the consensus average target of $138.25 and 33% upside to the high target of $163.00, against roughly 22% downside to the analyst low of $95.00 and about 40% downside to the 52-week low of $73.21. The 8.18x forward PE and 0.52 PEG suggest the market is pricing in substantial pessimism, while the core brand's 56.75% gross margin and $670.66 million in trailing free cash flow show the business remains highly cash-generative. The biggest downside risk is that HEYDUDE deterioration and revenue stagnation validate the bear case, turning the stock into a value trap. It is a good buy for value-oriented investors with a medium-to-long horizon who can tolerate the 1.514 beta and a potential 20-40% drawdown, but it is not suitable for conservative or income-focused portfolios given the 0% dividend yield.
CROX is better suited for medium-to-long-term investment than short-term trading, given the turnaround thesis depends on HEYDUDE stabilization and earnings normalization that will take several quarters to play out. The beta of 1.514 and maximum drawdown of -24.25% make it too volatile for most short-term traders unless they actively manage stops around the $108-111 support and $141.28 resistance levels. The 0% dividend yield and 0 payout ratio mean there is no income component to cushion the wait, so total return depends entirely on price appreciation. Earnings visibility is moderate: the forward EPS estimate of $14.83 has a tight range of $14.54-$15.09, but revenue estimates span $4.49-$4.62 billion, showing more uncertainty on the top line. A minimum holding period of 12-18 months is suggested to allow the HEYDUDE situation to resolve and the forward multiple to normalize.
